ArticleObesity (Silver Spring, Md.)2019
Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada.
Article in Obesity (Silver Spring, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021Pooled it
- Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome.Scientific reports · 2023Trial
- Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.JAMA network open · 2022Trial
- A Narrative Review of Weight Management Strategies: From Lifestyle Interventions to Emerging Pharmacotherapies.Journal of obesity · 2026Review
- Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.European journal of medical research · 2025Observational
- Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.International journal of molecular sciences · 2025Review
- GLP-1 and the Neurobiology of Eating Control: Recent Advances.Endocrinology · 2025Review
- Incretin-based therapies for the treatment of obesity-related diseases.npj metabolic health and disease · 2024Review
- Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study.Journal of clinical medicine · 2024Article
- One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice.JAMA network open · 2024Article
- Treatment with liraglutide or naltrexone-bupropion in patients with genetic obesity: a real-world study.EClinicalMedicine · 2024Article
- Sex-Differences in Response to Treatment with Liraglutide 3.0 mg.Journal of clinical medicine · 2024Article
- Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective.International journal of obesity (2005) · 2024Article
- Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting.Endocrine · 2024Observational
- Effectiveness and tolerability of liraglutide for the management of weight regain following sleeve gastrectomy.Obesity science & practice · 2024Article
- Safety and Effectiveness of Naltrexone-Bupropion in Korean Adults with Obesity: Post-Marketing Surveillance Study.Drug design, development and therapy · 2024Observational
- Evaluation of the Effectiveness of Liraglutide on Metabolic Parameters in the Treatment of Obesity.Cureus · 2023Article
- Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery.Biomedicines · 2023Article
- Five-year Weight Loss Maintenance With Obesity Pharmacotherapy.The Journal of clinical endocrinology and metabolism · 2023Article
- Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveReal-world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline.
methodsA cohort of liraglutide 3.0 mg initiators in 2015 and 2016 was identified from six Canadian weight-management clinics. Post initiation values at 4 and 6 months were compared with baseline values using a paired t test.
resultsThe full cohort consisted of 311 participants, with 210 in the ≥ 4-month persistence group and 167 in the ≥ 6-month persistence group. Average baseline BMI was 40.7 kg/m
conclusionsIn a real-world setting, liraglutide 3.0 mg, when combined with diet and exercise, was associated with clinically meaningful weight loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.